Education
About Us
Working with TipRanks
Follow Us
CNS Pharmaceuticals (CNSP)
NASDAQ:CNSP
CNSP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.99 - $801.91
Previous CloseN/A
Volume19.26M
Average Volume (3M)292.17K
Market Cap
$3.95M
Enterprise Value$2.37M
Total Cash (Recent Filing)$242.69K
Total Debt (Recent Filing)$121.83K
Price to Earnings (P/E)―
Beta1.98
Next Earnings
May 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-37.33
Shares Outstanding2,944,381
10 Day Avg. Volume213,819
30 Day Avg. Volume292,169
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-574.34
Enterprise Value/Ebitda-0.14
Forecast
1Y Price Target
$4.00Price Target Upside280.95% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
CNS Pharmaceuticals News
PremiumCompany Announcements
CNS Pharmaceuticals Advances TPI 287 for Glioblastoma
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityCNS Pharmaceuticals has been able to raise approximately $15M, providing sufficient cash runway into the first half of 2025.
New Asset AcquisitionCNS recently acquired a new asset, TPI-287, a chemotherapy in the taxane class that can cross into the brain.
Regulatory PotentialThe long-awaited Phase 2 study for Berubicin in second-line glioblastoma is expected to report top-line data, and if successful, CNS could be positioned to file for approval.
Bears Say
Analyst DowngradeAnalysts are removing Berubicin from their model and downgrading CNSP shares to Hold, from Buy.
Clinical Study ResultsBerubicin failed on the primary of overall survival vs. lomustine in the P2 second line glioblastoma study.
Stock PerformanceShares are down ~60% on the news of Berubicin's failure in the P2 study.
---
Options Prices
Currently, No data available
---
Ownership Overview
19.47%
Insiders
6.76% Mutual Funds
0.66% Other Institutional Investors
73.77% Public Companies and
Individual Investors
CNSP FAQ
What was CNS Pharmaceuticals’s price range in the past 12 months?
CNS Pharmaceuticals lowest stock price was $0.99 and its highest was $801.91 in the past 12 months.
What is CNS Pharmaceuticals’s market cap?
CNS Pharmaceuticals’s market cap is $3.95M.
When is CNS Pharmaceuticals’s upcoming earnings report date?
CNS Pharmaceuticals’s upcoming earnings report date is May 19, 2025 which is in 20 days.
How were CNS Pharmaceuticals’s earnings last quarter?
CNS Pharmaceuticals released its earnings results on Apr 07, 2025. The company reported -$37.33 earnings per share for the quarter, missing the consensus estimate of -$2 by -$35.33.
Is CNS Pharmaceuticals overvalued?
According to Wall Street analysts CNS Pharmaceuticals’s price is currently Undervalued.
Does CNS Pharmaceuticals pay dividends?
CNS Pharmaceuticals does not currently pay dividends.
What is CNS Pharmaceuticals’s EPS estimate?
CNS Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CNS Pharmaceuticals have?
CNS Pharmaceuticals has 2,944,381 shares outstanding.
What happened to CNS Pharmaceuticals’s price movement after its last earnings report?
CNS Pharmaceuticals reported an EPS of -$37.33 in its last earnings report, missing expectations of -$2. Following the earnings report the stock price went up 1.818%.
Which hedge fund is a major shareholder of CNS Pharmaceuticals?
Currently, no hedge funds are holding shares in CNSP
---
CNS Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.00 (280.95% Upside)
$4.00 (280.95% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-99.78%
12-Months-Change
Fundamentals
Return on Equity
-1703.39%
Trailing 12-Months
Asset Growth
411.56%
Trailing 12-Months
Company Description
CNS Pharmaceuticals
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
---
CNSP Stock 12 Month Forecast
Average Price Target
$4.00
▲(280.95% Upside)
Technical Analysis
Qualigen Therapeutics
―
Aptevo Therapeutics
―
Entero Therapeutics
―
Nucana
―
NLS Pharmaceutics
―
---